Iterum Therapeutics plc (ITRM) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Iterum Therapeutics plc (ITRM) Bundle
Discover the true potential of Iterum Therapeutics plc (ITRM) with our advanced DCF Calculator! Adjust essential assumptions, explore various scenarios, and evaluate the effects of changes on Iterum Therapeutics plc (ITRM) valuation – all within a convenient Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -100 | 0 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -101.7 | -36.0 | -83.2 | -40.0 | -34.6 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -274791.89 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .2 | .2 | 2.1 | 1.8 | 1.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 410.81 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -101.8 | -36.2 | -85.3 | -41.8 | -36.3 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -275202.7 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 4.8 | 14.5 | 81.3 | 60.8 | 23.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.1 | .9 | 1.2 | .0 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 2983.78 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -8.0 | -3.7 | -3.1 | -1.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | -21697.3 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 15.5 | .8 | .9 | 2.8 | 5.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 41854.05 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -64.86 | 100 | 100 | 100 | 100 | -12.97 | -12.97 | -12.97 | -12.97 | -12.97 |
| Tax Rate, % | -1.62 | -1.62 | -1.62 | -1.62 | -1.62 | -1.62 | -1.62 | -1.62 | -1.62 | -1.62 |
| EBITAT | -102.3 | -36.7 | -86.0 | -42.1 | -36.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -79.7 | -55.3 | -84.8 | -38.5 | -35.0 | -4.8 | .0 | .0 | .0 | .0 |
| WACC, % | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | 13 | |||||||||
| Equity Value | -17 | |||||||||
| Diluted Shares Outstanding, MM | 13 | |||||||||
| Equity Value Per Share | -1.33 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled real ITRM financials.
- Actual Data: Historical figures and forward-looking projections (highlighted in the yellow cells).
- Forecast Adaptability: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe the effects of your inputs on Iterum Therapeutics' valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- User-Centric Layout: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Comprehensive ITRM Data: Pre-loaded with Iterum Therapeutics' historical performance metrics and future projections.
- Customizable Variables: Modify assumptions for revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Framework: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to explore different valuation possibilities.
- User-Centric Interface: Intuitive, organized, and suitable for both industry experts and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based ITRM DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Iterum Therapeutics' intrinsic value.
- Test Scenarios: Experiment with varying assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Iterum Therapeutics plc (ITRM)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Iterum Therapeutics.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for (ITRM).
- Detailed Insights: Automatically computes Iterum’s intrinsic value and Net Present Value for informed decision-making.
- Preloaded Data: Features historical and projected data for (ITRM) to provide reliable starting points.
- Professional Quality: Perfect for financial analysts, investors, and consultants focused on Iterum Therapeutics.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Iterum Therapeutics plc (ITRM) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Iterum Therapeutics plc (ITRM).
- Consultants: Deliver professional valuation insights on Iterum Therapeutics plc (ITRM) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Iterum Therapeutics plc (ITRM) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Iterum Therapeutics plc (ITRM).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Iterum Therapeutics plc (ITRM) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Iterum Therapeutics plc (ITRM).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.